Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.53M | -20.97M | -17.00M | -15.65M | -11.76M |
| Total Depreciation and Amortization | 14.50K | 7.40K | 7.40K | 5.90K | 5.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.04M | 5.73M | 1.93M | 2.77M | 2.89M |
| Change in Net Operating Assets | -734.80K | 749.40K | 802.90K | -124.20K | 263.90K |
| Cash from Operations | -18.21M | -14.49M | -14.26M | -13.01M | -8.60M |
| Capital Expenditure | -4.40K | -5.10K | -12.60K | -14.90K | -13.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.85M | 269.70K | -12.71M | -14.43M | -12.88M |
| Cash from Investing | 4.84M | 264.60K | -12.72M | -14.45M | -12.89M |
| Total Debt Issued | -- | 140.00K | 139.00K | 140.00K | 2.38M |
| Total Debt Repaid | -- | -237.00K | -2.62M | -2.62M | -2.62M |
| Issuance of Common Stock | 43.64M | 2.92M | 2.70M | 35.16M | 35.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.85M | -3.19M | -2.83M | 15.50M | 15.51M |
| Cash from Financing | 38.21M | -270.30K | -1.94M | 35.87M | 37.53M |
| Foreign Exchange rate Adjustments | 540.00K | -897.90K | 236.60K | -641.70K | -849.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.38M | -15.39M | -28.68M | 7.77M | 15.19M |
